Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up

Jeong Hoon Lee, Joon Hyeok Lee, Young Suk Lim, Jong Eun Yeon, Taejin Song, Su Jong Yu, Geum Youn Gwak, Kang Mo Kim, Yoon Jun Kim, Jae Won Lee, Jung Hwan Yoon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if the efficacy of CIK cell therapy continued after end of repeated CIK cell injections. We performed a follow-up study of our preceding trial. We included 226 patients: 114 patients in the immunotherapy group (injection of 6.4 × 109 CIK cells, 16 times during 60 weeks) and 112 patients in the control group (no treatment) after potentially curative treatment for HCC. In total, 162 patients (89 of the immunotherapy group and 73 of controls) underwent an extended follow-up for 60 months after randomization of the last patient. The primary endpoint was RFS, and secondary endpoints included OS. During follow-up time of median 68.5 months (interquartile range 45.0–82.2 months), the immunotherapy group continued to show a significantly lower risk of recurrence or death [hazard ratio (HR) 0.67; 95% confidence interval (CI) 0.48–0.94; P = 0.009 by one-sided log-rank test]. At 5 years, RFS rate was 44.8% in the immunotherapy group and 33.1% in the control group. The risk of all-cause death was also lower in the immunotherapy group compared to the control group (HR 0.33; 95% CI 0.15–0.76; P = 0.006). In patients who received curative treatment for HCC, the significant improvement in RFS and OS as a result of adjuvant CIK cell immunotherapy lasted over 5 years without boosting.

Original languageEnglish
JournalCancer Immunology, Immunotherapy
DOIs
Publication statusAccepted/In press - 2018 Jan 1

Fingerprint

Cytokine-Induced Killer Cells
Immunotherapy
Hepatocellular Carcinoma
Survival
Recurrence
Control Groups
Confidence Intervals
Injections
Therapeutics
Random Allocation
Cell- and Tissue-Based Therapy
Cause of Death
Survival Rate
Randomized Controlled Trials

Keywords

  • Adjuvant immunotherapy
  • Cytokine-induced killer cell
  • Hepatocellular carcinoma
  • Overall survival
  • Recurrence-free survival

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma : an extended 5-year follow-up. / Lee, Jeong Hoon; Lee, Joon Hyeok; Lim, Young Suk; Yeon, Jong Eun; Song, Taejin; Yu, Su Jong; Gwak, Geum Youn; Kim, Kang Mo; Kim, Yoon Jun; Lee, Jae Won; Yoon, Jung Hwan.

In: Cancer Immunology, Immunotherapy, 01.01.2018.

Research output: Contribution to journalArticle

Lee, Jeong Hoon ; Lee, Joon Hyeok ; Lim, Young Suk ; Yeon, Jong Eun ; Song, Taejin ; Yu, Su Jong ; Gwak, Geum Youn ; Kim, Kang Mo ; Kim, Yoon Jun ; Lee, Jae Won ; Yoon, Jung Hwan. / Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma : an extended 5-year follow-up. In: Cancer Immunology, Immunotherapy. 2018.
@article{15eee4d81e0c470898117781f4b310fb,
title = "Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up",
abstract = "Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if the efficacy of CIK cell therapy continued after end of repeated CIK cell injections. We performed a follow-up study of our preceding trial. We included 226 patients: 114 patients in the immunotherapy group (injection of 6.4 × 109 CIK cells, 16 times during 60 weeks) and 112 patients in the control group (no treatment) after potentially curative treatment for HCC. In total, 162 patients (89 of the immunotherapy group and 73 of controls) underwent an extended follow-up for 60 months after randomization of the last patient. The primary endpoint was RFS, and secondary endpoints included OS. During follow-up time of median 68.5 months (interquartile range 45.0–82.2 months), the immunotherapy group continued to show a significantly lower risk of recurrence or death [hazard ratio (HR) 0.67; 95{\%} confidence interval (CI) 0.48–0.94; P = 0.009 by one-sided log-rank test]. At 5 years, RFS rate was 44.8{\%} in the immunotherapy group and 33.1{\%} in the control group. The risk of all-cause death was also lower in the immunotherapy group compared to the control group (HR 0.33; 95{\%} CI 0.15–0.76; P = 0.006). In patients who received curative treatment for HCC, the significant improvement in RFS and OS as a result of adjuvant CIK cell immunotherapy lasted over 5 years without boosting.",
keywords = "Adjuvant immunotherapy, Cytokine-induced killer cell, Hepatocellular carcinoma, Overall survival, Recurrence-free survival",
author = "Lee, {Jeong Hoon} and Lee, {Joon Hyeok} and Lim, {Young Suk} and Yeon, {Jong Eun} and Taejin Song and Yu, {Su Jong} and Gwak, {Geum Youn} and Kim, {Kang Mo} and Kim, {Yoon Jun} and Lee, {Jae Won} and Yoon, {Jung Hwan}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00262-018-2247-4",
language = "English",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",

}

TY - JOUR

T1 - Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma

T2 - an extended 5-year follow-up

AU - Lee, Jeong Hoon

AU - Lee, Joon Hyeok

AU - Lim, Young Suk

AU - Yeon, Jong Eun

AU - Song, Taejin

AU - Yu, Su Jong

AU - Gwak, Geum Youn

AU - Kim, Kang Mo

AU - Kim, Yoon Jun

AU - Lee, Jae Won

AU - Yoon, Jung Hwan

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if the efficacy of CIK cell therapy continued after end of repeated CIK cell injections. We performed a follow-up study of our preceding trial. We included 226 patients: 114 patients in the immunotherapy group (injection of 6.4 × 109 CIK cells, 16 times during 60 weeks) and 112 patients in the control group (no treatment) after potentially curative treatment for HCC. In total, 162 patients (89 of the immunotherapy group and 73 of controls) underwent an extended follow-up for 60 months after randomization of the last patient. The primary endpoint was RFS, and secondary endpoints included OS. During follow-up time of median 68.5 months (interquartile range 45.0–82.2 months), the immunotherapy group continued to show a significantly lower risk of recurrence or death [hazard ratio (HR) 0.67; 95% confidence interval (CI) 0.48–0.94; P = 0.009 by one-sided log-rank test]. At 5 years, RFS rate was 44.8% in the immunotherapy group and 33.1% in the control group. The risk of all-cause death was also lower in the immunotherapy group compared to the control group (HR 0.33; 95% CI 0.15–0.76; P = 0.006). In patients who received curative treatment for HCC, the significant improvement in RFS and OS as a result of adjuvant CIK cell immunotherapy lasted over 5 years without boosting.

AB - Our earlier multicenter randomized controlled trial showed that adjuvant immunotherapy with cytokine-induced killer (CIK) cells resulted in longer recurrence-free survival (RFS) and overall survival (OS) as well in patients who received curative treatment for hepatocellular carcinoma (HCC). In the present study, we determined if the efficacy of CIK cell therapy continued after end of repeated CIK cell injections. We performed a follow-up study of our preceding trial. We included 226 patients: 114 patients in the immunotherapy group (injection of 6.4 × 109 CIK cells, 16 times during 60 weeks) and 112 patients in the control group (no treatment) after potentially curative treatment for HCC. In total, 162 patients (89 of the immunotherapy group and 73 of controls) underwent an extended follow-up for 60 months after randomization of the last patient. The primary endpoint was RFS, and secondary endpoints included OS. During follow-up time of median 68.5 months (interquartile range 45.0–82.2 months), the immunotherapy group continued to show a significantly lower risk of recurrence or death [hazard ratio (HR) 0.67; 95% confidence interval (CI) 0.48–0.94; P = 0.009 by one-sided log-rank test]. At 5 years, RFS rate was 44.8% in the immunotherapy group and 33.1% in the control group. The risk of all-cause death was also lower in the immunotherapy group compared to the control group (HR 0.33; 95% CI 0.15–0.76; P = 0.006). In patients who received curative treatment for HCC, the significant improvement in RFS and OS as a result of adjuvant CIK cell immunotherapy lasted over 5 years without boosting.

KW - Adjuvant immunotherapy

KW - Cytokine-induced killer cell

KW - Hepatocellular carcinoma

KW - Overall survival

KW - Recurrence-free survival

UR - http://www.scopus.com/inward/record.url?scp=85053713401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053713401&partnerID=8YFLogxK

U2 - 10.1007/s00262-018-2247-4

DO - 10.1007/s00262-018-2247-4

M3 - Article

C2 - 30232520

AN - SCOPUS:85053713401

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

ER -